Number of the records: 1
Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines
- 1.
SYSNO ASEP 0191582 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Ostatní články Title Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines Author(s) Indrová, Marie (UMG-J) RID
Bubeník, Jan (UMG-J)
Mikyšková, Romana (UMG-J) RID
Mendoza, Luis (UMG-J)
Šímová, Jana (UMG-J) RID
Bieblová, Jana (UMG-J)
Jandlová, Táňa (UMG-J)
Jinoch, P. (CZ)
Šmahel, M. (CZ)
Vonka, V. (CZ)
Pajtasz-Piasecka, E. (PL)Source Title International Journal of Oncology. - : Spandidos Publications - ISSN 1019-6439
Roč. 22, č. 3 (2003), s. 691-695Number of pages 5 s. Language eng - English Country GR - Greece Keywords chemotherapy-induced residual tumour disease ; immunotherapy ; HPV16-associated tumours Subject RIV FD - Oncology ; Hematology R&D Projects NC7148 GA MZd - Ministry of Health (MZ) GA301/00/0114 GA ČR - Czech Science Foundation (CSF) GA301/01/0985 GA ČR - Czech Science Foundation (CSF) IAA5052203 GA AV ČR - Academy of Sciences of the Czech Republic (AV ČR) IAA7052002 GA AV ČR - Academy of Sciences of the Czech Republic (AV ČR) CEZ AV0Z5052915 - UMG-J Annotation The effectiveness of chemoimmunotherapy with ifosfamide derivative CBM-4A and recombinant IL-2, IL-12, GM-CSF, or genetically modified, cytokine-producing tumour vaccines was examined in mice carrying HPV16-associated, MHC class I+ and class I- tumours. In mice carrying the MHC class I- tumour the effects of adjuvant cytokine therapy were substantially weaker than in mice carrying MHC class I+ tumour inoculum. Workplace Institute of Molecular Genetics Contact Nikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217 Year of Publishing 2004
Number of the records: 1